Detected substances among patients with confirmed bromazolam exposure who present to the emergency department following a suspected opioid and/or stimulant-related non-fatal overdose
- 7 July 2025
- journal article
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 274, 112776
Abstract
No abstract availableKeywords
Funding Information
- US Food and Drug Administration (75F40122D00028/75F40123F19002)
This publication has 10 references indexed in Scilit:
- A postmortem case report involving fentanyl, desalkylgidazepam, and bromazolamJournal of Analytical Toxicology, 2024
- In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole ‘nitazene’ opioidsArchives of Toxicology, 2024
- The surge of bromazolam‐related fatalities replacing other novel designer benzodiazepines‐related fatalities in San FranciscoAddiction, 2024
- Notes from the Field: Seizures, Hyperthermia, and Myocardial Injury in Three Young Adults Who Consumed Bromazolam Disguised as Alprazolam — Chicago, Illinois, February 2023MMWR. Morbidity and Mortality Weekly Report, 2024
- Post mortem blood bromazolam concentrations and co-findings in 96 coronial cases within England and WalesForensic Science International, 2023
- Bromazolam Blood Concentrations in Postmortem Cases—A British Columbia PerspectiveJournal of Analytical Toxicology, 2023
- The Emerging Role of Toxic Adulterants in Street Drugs in the US Illicit Opioid CrisisPublic Health Reports®, 2019
- The epidemiology of benzodiazepine misuse: A systematic reviewDrug and Alcohol Dependence, 2019
- Levamisole: A High Performance Cutting AgentAcademic Forensic Pathology, 2017
- Imputing defensible values for left-censored ‘below level of quantitation’ (LoQ) biomarker measurementsJournal of Breath Research, 2016